James Thornton, venture capital investor, discusses Mylan CEO Heather Bresch's explanation for the pricing of the EpiPen. CNBC Contributor Bill George, former CEO of Medtronic, and Darnisha Harrison, Ennaid Therapeutics CEO, weigh in.
CNBC Contributor Bill George, former CEO of Medtronic, and Darnisha Harrison, Ennaid Therapeutics CEO, discuss the controversy surrounding Mylan's pricing of the EpiPen and the FDA's guidelines for drug development.
CNBC Contributor Bill George, former CEO of Medtronic, and Darnisha Harrison, Ennaid Therapeutics CEO, discuss the controversy surrounding Mylan's pricing of the EpiPen and whether America's health care system is broken.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
The "FMHR" panel and David Maris, specialty pharmaceutical analyst at Wells Fargo Securities, discuss the latest on the EpiPen pricing outrage.
Mylan hiked prices in the midst of heated U.S. elections where both candidates agreed that drug prices are too high, says WBB Securities' Steve Brozak.
Umer Raffat, Evercore ISI Senior Analyst, discusses how Mylan's stock price may be affected long-term by the EpiPen pricing saga.
The "Fast Money" traders discuss the effect of Mylan's EpiPen pricing controversy on the biotech sector.
Paul Howard, Manhattan Institute Senior Fellow director of the Center for Medical Progress, and Robert Weissman, Public Citizen president, share their take on Mylan, the EpiPen pricing outrage and regulation versus the free market.
CNBC's Meg Tirrell reports the latest on Mylan and the EpiPen pricing outrage.
Peter Pitts, former FDA associate commissioner and Center for Medicine in the Public Interest president, discusses FDA's role in the Mylan EpiPen outrage.
CNBC's Jim Cramer says Wednesday that Mylan's lifesaving EpiPen device shouldn't be only obtainable for the rich.
CNBC's Meg Tirrell reports on other price hikes from Mylan apart from its controversial raise of its EpiPen. The "Fast Money" traders weigh in on the drug pricing debate.
Ron Cohen, Acorda Therapeutics President & CEO, and CNBC's Meg Tirrell discuss the outrage surrounding Mylan's EpiPen price hike and the general state of drug pricing and development.
Tim Chiang, BTIG managing director, shares his take on Mylan, admid the EpiPen price outrage.
Sen. Richard Blumenthal (D-Conn.), Former Connecticut Attorney General, discusses the outrage over the price hike on Mylan's EpiPen.
A probe into the Canadian company centers on whether it defrauded insurers by hiding ties with Philidor.
The pharmaceutical company reported its cancer drug failed to reach its goals for treating advanced non-small cell lung cancer.
Teva Pharmaceutical Industries' Yitzhak Peterburg says business is running as usual as it is still too early to determine Brexit's impact.
CNBC's Meg Tirrell talks with Merck's Roger Perlmutter about advances the drugmaker has made in treating cancer, including immunotherapy drug KEYTRUDA. Perlmutter also addresses concerns over the high price of drugs.